


PHARMACEUTICAL 2018

## Innovation1 Biotech Inc. Rank 289 of 349









PHARMACEUTICAL 2018



## Innovation1 Biotech Inc. Rank 289 of 349

The relative strengths and weaknesses of Innovation1 Biotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Innovation1 Biotech Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 1,655% points. The greatest weakness of Innovation1 Biotech Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 222% points.

The company's Economic Capital Ratio, given in the ranking table, is -533%, being 256% points below the market average of -278%.

| Input Variable                              | Value in 1000 USD |
|---|-------------------|
| Assets, Current                             | 0                 |
| Cost of Goods Sold                          | 0                 |
| Intangible Assets                           | 0                 |
| Liabilities, Current                        | 0.77              |
| Liabilities, Non-Current                    | 0                 |
| Other Assets                                | 6.8               |
| Other Compr. Net Income                     | 0                 |
| Other Expenses                              | 22                |
| Other Liabilities                           | 76                |
| Other Net Income                            | 0                 |
| Property and Equipment                      | 0                 |
| Research and Development                    | 0                 |
| Revenues                                    | 0                 |
| Selling, General and Administrative Expense | 14                |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 6.8               |
| Liabilities              | 77                |
| Expenses                 | 36                |
| Stockholders Equity      | -70               |
| Net Income               | -36               |
| Comprehensive Net Income | -36               |
| Economic Capital Ratio   | -533%             |

